U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H16Br2N2O2
Molecular Weight 356.054
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PIPOBROMAN

SMILES

BrCCC(=O)N1CCN(CC1)C(=O)CCBr

InChI

InChIKey=NJBFOOCLYDNZJN-UHFFFAOYSA-N
InChI=1S/C10H16Br2N2O2/c11-3-1-9(15)13-5-7-14(8-6-13)10(16)2-4-12/h1-8H2

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including: http://www.drugbank.ca/drugs/DB00236

Pipobroman (trade names Vercite, Vercyte) is an anti-cancer drug that probably acts as an alkylating agent. It is marketed by Abbott Laboratories. Pipobroman (PB) has well documented clinical activity in polycythemia vera (PV) and essential thrombocythemia (ET). The mechanism of action is uncertain but pipobroman is thought to alkylate DNA leading to disruption of DNA synthesis and eventual cell death

Originator

Sources: Roczniki Chemii (1960), 34, 707-8. 

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: CHEMBL2311221
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
VERCYTE

Approved Use

Pipobroman

Launch Date

-1.25711999E11
Primary
VERCYTE

Approved Use

Pipobroman

Launch Date

-1.25711999E11
Doses

Doses

DosePopulationAdverse events​
75 mg 1 times / day multiple, oral
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg, 1 times / day
Sources:
unhealthy, 61.8
n = 140
Health Status: unhealthy
Condition: polycythemia vera
Age Group: 61.8
Sex: M+F
Population Size: 140
Sources:
Disc. AE: Pancytopenia, Gastric pain...
AEs leading to
discontinuation/dose reduction:
Pancytopenia
Gastric pain
Diarrhea
Aplasia bone marrow
Sources:
AEs

AEs

AESignificanceDosePopulation
Aplasia bone marrow Disc. AE
75 mg 1 times / day multiple, oral
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg, 1 times / day
Sources:
unhealthy, 61.8
n = 140
Health Status: unhealthy
Condition: polycythemia vera
Age Group: 61.8
Sex: M+F
Population Size: 140
Sources:
Diarrhea Disc. AE
75 mg 1 times / day multiple, oral
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg, 1 times / day
Sources:
unhealthy, 61.8
n = 140
Health Status: unhealthy
Condition: polycythemia vera
Age Group: 61.8
Sex: M+F
Population Size: 140
Sources:
Gastric pain Disc. AE
75 mg 1 times / day multiple, oral
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg, 1 times / day
Sources:
unhealthy, 61.8
n = 140
Health Status: unhealthy
Condition: polycythemia vera
Age Group: 61.8
Sex: M+F
Population Size: 140
Sources:
Pancytopenia Disc. AE
75 mg 1 times / day multiple, oral
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg, 1 times / day
Sources:
unhealthy, 61.8
n = 140
Health Status: unhealthy
Condition: polycythemia vera
Age Group: 61.8
Sex: M+F
Population Size: 140
Sources:
PubMed

PubMed

TitleDatePubMed
Bone marrow aplasia after pipobroman: an immune-mediated mechanism?
2001 Dec
Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea.
2002 Oct
[Polycythemia vera].
2002 Oct 15
Transition of essential thrombocythemia to megakaryoblastic leukemia after long-term therapy with sequential busulfan, pipobroman and hydroxyurea.
2003
Polycythemia vera.
2003 Oct
Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman.
2003 Sep
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman.
2004 Aug
Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study.
2005 Apr 1
Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
2006 Jun
Essential thrombocythemia.
2007 Jan 8
A review of the therapeutic agents used in the management of polycythaemia vera.
2007 Jun
The treatment of polycythaemia vera: an update in the JAK2 era.
2007 Mar
Practical approach to treating essential thrombocythaemia: case studies.
2007 Oct
A case of bromoderma and bromism.
2008 Feb
Essential thrombocythemia: past and present.
2009 Oct
Inhibition of allogeneic inflammatory responses by the Ribonucleotide Reductase Inhibitors, Didox and Trimidox.
2010 Aug 18
Polycythemia vera.
2010 Oct
Patents

Sample Use Guides

Polycythemia vera: 1 mg/kg/day Chronic granulocytic leukemia: 1.5-2.5 mg/kg/day
Route of Administration: Oral
In Vitro Use Guide
Unknown
Name Type Language
PIPOBROMAN
HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
PIPOBROMAN [JAN]
Common Name English
PIPOBROMAN [HSDB]
Common Name English
Pipobroman [WHO-DD]
Common Name English
A-8103
Code English
1,4-Bis(3-bromopropionyl)piperazine
Systematic Name English
PIPERAZINE, 1,4-BIS(3-BROMO-1-OXOPROPYL)-
Systematic Name English
PIPOBROMAN [USAN]
Common Name English
VERCYTE
Brand Name English
PIPOBROMAN [ORANGE BOOK]
Common Name English
pipobroman [INN]
Common Name English
PIPOBROMAN [VANDF]
Common Name English
NSC-25154
Code English
PIPOBROMAN [MART.]
Common Name English
PIPOBROMAN [MI]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1590
Created by admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
WHO-ATC L01AX02
Created by admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
WHO-VATC QL01AX02
Created by admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
Code System Code Type Description
CAS
54-91-1
Created by admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
PRIMARY
IUPHAR
7271
Created by admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
PRIMARY
ChEMBL
CHEMBL1585
Created by admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
PRIMARY
RXCUI
8347
Created by admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
PRIMARY RxNorm
WIKIPEDIA
PIPOBROMAN
Created by admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
PRIMARY
SMS_ID
100000092245
Created by admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
PRIMARY
INN
2049
Created by admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
PRIMARY
PUBCHEM
4842
Created by admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
PRIMARY
HSDB
3249
Created by admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
PRIMARY
DRUG CENTRAL
2192
Created by admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
PRIMARY
DRUG BANK
DB00236
Created by admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
PRIMARY
EPA CompTox
DTXSID7023485
Created by admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
PRIMARY
NCI_THESAURUS
C750
Created by admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
PRIMARY
MERCK INDEX
m8863
Created by admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
PRIMARY Merck Index
EVMPD
SUB09875MIG
Created by admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
PRIMARY
CHEBI
8242
Created by admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
PRIMARY
MESH
D010885
Created by admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
PRIMARY
FDA UNII
6Q99RDT97R
Created by admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
PRIMARY
NSC
25154
Created by admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
PRIMARY